It is interesting to note that these active compounds act in a multi-targeted manner, such as regulating the levels of AMPK, PPAR, SREBP-1c, FAS, ACC, SIRT1, Nrf2, JNK and other proteins to improve NAFLD. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.